norfloxacin has been researched along with E coli Infections in 85 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and safety of a 5-day course of treatment with the new oral penem agent ritipenem acoxil (500 mg three times daily) or with norfloxacin (200 mg twice daily) were assessed in a double-blind study of women with uncomplicated cystitis." | 9.08 | Interpretation of the bacteriologic outcome of antibiotic treatment for uncomplicated cystitis: impact of the definition of significant bacteriuria in a comparison of ritipenem acoxil with norfloxacin. Swedish Urinary Tract Infection Study Group. ( , 1995) |
| "The efficacy and safety of rufloxacin (400 mg, single dose) were compared to those of norfloxacin (400 mg twice a day for 3 days) for the treatment of women with uncomplicated cystitis." | 9.08 | Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations. ( Aguilar, L; Caffaratti, J; Dal-Ré, R; Dalet, F; Del Río, G, 1996) |
| "Two-hundred nine patients with symptoms of acute urinary tract infection and pyuria were randomized to 400 mg of administered norfloxacin twice daily for three days, or 800 mg of sulfamethoxazole and 160 mg of trimethoprim administered twice daily for ten days." | 9.06 | A multicenter comparative trial of three-day norfloxacin vs ten-day sulfamethoxazole and trimethoprim for the treatment of uncomplicated urinary tract infections. ( Boyko, EJ; Cox, CE; Goldstein, EJ; Kurtz, TO; Miller, K; Mummaw, N; Reller, LB; Stein, GE, 1987) |
| "We treated 15 men who had chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin with 400 mg." | 7.68 | The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin. ( Darras, FS; Schaeffer, AJ, 1990) |
| "The therapeutic efficacy of the fluoroquinolone pefloxacin mesylate was compared with those of cefotaxime and chloramphenicol in a rabbit model of Escherichia coli meningitis." | 7.67 | Evaluation of pefloxacin in experimental Escherichia coli meningitis. ( Hackbarth, CJ; Sande, MA; Shibl, AM, 1986) |
| "28 patients with urinary tract infections (UTI) were treated with norfloxacin 2 X 400 mg daily for 9 days." | 7.67 | [Norfloxacin in the treatment of urinary tract infections]. ( Joost, J, 1986) |
| "At the end of 5 days of treatment, diarrhea had resolved in 100% of 73 patients receiving norfloxacin and 97." | 6.67 | Norfloxacin compared to trimethoprim/sulfamethoxazole for the treatment of travelers' diarrhea among U.S. military personnel deployed to South America and West Africa. ( Batchelor, RA; Bourgeois, AL; Burr, DH; Gardiner, C; Garst, P; Hyams, KC; Kilpatrick, ME; Oprandy, JJ; Thornton, SA; Wignall, SF, 1992) |
| "treatment with norfloxacin 200 mg or 400 mg or trimethoprim/sulfamethoxazole." | 6.66 | Norfloxacin versus co-trimoxazole for treatment of urinary tract infections in adults: microbiological results of a coordinated multicentre study. ( Norrby, SR; Rylander, M; Svärd, R, 1987) |
| "The efficacy and safety of a 5-day course of treatment with the new oral penem agent ritipenem acoxil (500 mg three times daily) or with norfloxacin (200 mg twice daily) were assessed in a double-blind study of women with uncomplicated cystitis." | 5.08 | Interpretation of the bacteriologic outcome of antibiotic treatment for uncomplicated cystitis: impact of the definition of significant bacteriuria in a comparison of ritipenem acoxil with norfloxacin. Swedish Urinary Tract Infection Study Group. ( , 1995) |
| "The efficacy and safety of rufloxacin (400 mg, single dose) were compared to those of norfloxacin (400 mg twice a day for 3 days) for the treatment of women with uncomplicated cystitis." | 5.08 | Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations. ( Aguilar, L; Caffaratti, J; Dal-Ré, R; Dalet, F; Del Río, G, 1996) |
| "Norfloxacin, a broad-spectrum antimicrobial analog of nalidixic acid, was evaluated by comparing it to trimethoprim-sulfamethoxazole in 93 office patients with recurrent urinary tract infections." | 5.06 | Treatment of recurrent urinary tract infection with norfloxacin versus trimethoprim-sulfamethoxazole. ( Amy, BG; Childs, SJ; Hurst, AT; Krisch, EB; McCabe, RE; Seidmon, EJ; Truant, AL, 1990) |
| " The treatment of 37 initial febrile episodes (12 cases of septicemia, 7 infectious sites and 38 cases of fever of unknown origin) in 33 neutropenic patients (PMN leucocytes less than 500/mm3) using the combination of a third generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacin) resulted in an 86% immediate success rate (32 cases/37)." | 5.06 | [Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)]. ( Bielefeld, P; Caillot, D; Guy, H; Kazmierczak, A; Portier, H; Solary, E, 1987) |
| "Two-hundred nine patients with symptoms of acute urinary tract infection and pyuria were randomized to 400 mg of administered norfloxacin twice daily for three days, or 800 mg of sulfamethoxazole and 160 mg of trimethoprim administered twice daily for ten days." | 5.06 | A multicenter comparative trial of three-day norfloxacin vs ten-day sulfamethoxazole and trimethoprim for the treatment of uncomplicated urinary tract infections. ( Boyko, EJ; Cox, CE; Goldstein, EJ; Kurtz, TO; Miller, K; Mummaw, N; Reller, LB; Stein, GE, 1987) |
| "Norfloxacin decreases the incidence of spontaneous bacterial peritonitis in cirrhotics, but promotes the appearance of quinolone-resistant Escherichia coli." | 3.72 | Role of immunosuppression in the development of quinolone-resistant Escherichia coli spontaneous bacterial peritonitis and in the mortality of E. coli spontaneous bacterial peritonitis. ( Cereto, F; Del Valle, O; Esteban, R; Genescà, J; González, A; Guardia, J; Molina, I, 2003) |
| " Norfloxacin 400 mg per day had been introduced three months earlier as secondary prophylaxis for spontaneous bacterial peritonitis." | 3.72 | [Spontaneous infection of ascitic fluid due to Salmonella typhimurium in a cirrhotic patient undergoing selective intestinal decontamination with norfloxacin]. ( Colin, R; Di Fiore, F; Goria, O; Hervé, S; Lecleire, S; Lerebours, E; Savoye, G, 2003) |
| "Prophylaxis with norfloxacin has been shown to be effective in preventing spontaneous bacterial peritonitis (SBP) in liver cirrhosis." | 3.71 | Spontaneous bacterial peritonitis caused by quinolone-resistant Escherichia coli: could steroid therapy play a role? ( Cereto, F; del Valle Ortiz, O; Esteban, R; Genescà, J; González, A; Guardia, J; Moreno, G; Smithson, A, 2002) |
| "We designed a prospective study to evaluate the incidence of Escherichia coli in stools at admission in patients with cirrhosis that had previously received norfloxacin as primary or secondary prophylaxis of spontaneous bacterial peritonitis (SBP) (group I, n = 28) vs those who did not (group II, n = 55)." | 3.70 | [Development of Escherichia coli strands resistant to quinolones in stools of patients with liver cirrhosis submitted to selective bowel decontamination]. ( Aparicio, JR; Arroyo, A; Gutiérrez, A; Pérez-Mateo, M; Plaza, J; Such, J, 1999) |
| "In continuous surveillance of routine samples from five Dutch laboratories, we studied resistance to the antibiotics most commonly prescribed for urinary tract infections (UTI) in The Netherlands, namely norfloxacin, amoxycillin, trimethoprim and nitrofurantoin, from 1989 to 1998 in >90000 Escherichia coli isolates." | 3.70 | Increasing resistance to fluoroquinolones in escherichia coli from urinary tract infections in the netherlands. ( Buiting, AG; de Neeling, AJ; Goettsch, W; Hendrix, MG; Nagelkerke, N; Petit, PL; Sabbe, LJ; van Griethuysen, AJ; van Pelt, W, 2000) |
| "We treated 15 men who had chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin with 400 mg." | 3.68 | The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin. ( Darras, FS; Schaeffer, AJ, 1990) |
| "The effect of a single day treatment with 600 mg norfloxacin 600 mg ofloxacin or 1,920 mg trimethoprim-sulfamethoxazol was determined on 114 patients with acute cystitis." | 3.67 | [Single day treatment in acute cystitis]. ( Kawaguchi, K; Yamaguchi, K, 1988) |
| "The therapeutic efficacy of the fluoroquinolone pefloxacin mesylate was compared with those of cefotaxime and chloramphenicol in a rabbit model of Escherichia coli meningitis." | 3.67 | Evaluation of pefloxacin in experimental Escherichia coli meningitis. ( Hackbarth, CJ; Sande, MA; Shibl, AM, 1986) |
| "28 patients with urinary tract infections (UTI) were treated with norfloxacin 2 X 400 mg daily for 9 days." | 3.67 | [Norfloxacin in the treatment of urinary tract infections]. ( Joost, J, 1986) |
| " Using this model, the efficacy of two different dosing methods of norfloxacin (continuous and pulse dosing) was evaluated." | 2.70 | Pulse and continuous oral norfloxacin treatment of experimentally induced Escherichia coli infection in broiler chicks and turkey poults. ( Horváth, E; Laczay, P; Sárközy, G; Schmidt, J; Semjén, G, 2002) |
| "At the end of 5 days of treatment, diarrhea had resolved in 100% of 73 patients receiving norfloxacin and 97." | 2.67 | Norfloxacin compared to trimethoprim/sulfamethoxazole for the treatment of travelers' diarrhea among U.S. military personnel deployed to South America and West Africa. ( Batchelor, RA; Bourgeois, AL; Burr, DH; Gardiner, C; Garst, P; Hyams, KC; Kilpatrick, ME; Oprandy, JJ; Thornton, SA; Wignall, SF, 1992) |
| "treatment with norfloxacin 200 mg or 400 mg or trimethoprim/sulfamethoxazole." | 2.66 | Norfloxacin versus co-trimoxazole for treatment of urinary tract infections in adults: microbiological results of a coordinated multicentre study. ( Norrby, SR; Rylander, M; Svärd, R, 1987) |
| "The aac(6')-Ib-cr gene, in spite of producing low-level resistance by itself, plays a relevant role in acquisition of a clinical level of ciprofloxacin and norfloxacin resistance, when combined with three or four chromosomal mutations, both in vitro and in vivo." | 1.43 | Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli. ( Díaz-De-Alba, P; Docobo-Perez, F; Machuca, J; Ortiz, M; Pascual, Á; Recacha, E; Rodríguez-Martínez, JM, 2016) |
| "Norfloxacin 400 mg ? 2 was given for 3 days as prophylaxis starting just before or within 10 min of biopsy." | 1.37 | Febrile reactions after transrectal ultrasound-guided prostatic biopsy: a retrospective study. ( Claesson, BE; Hedelin, H; Wilpart, A, 2011) |
| "Most nonenteric E coli infections in dogs involve the urinary tract." | 1.31 | Nonenteric Escherichia coli isolates from dogs: 674 cases (1990-1998). ( Burke, TJ; Campbell, KL; Kakoma, I; Kim, CH; Koo, HY; McKiernan, BC; Oluoch, AO; Siegel, AM; Weisiger, RM, 2001) |
| "Norfloxacin was marginally bound to serum protein." | 1.30 | Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ( Gips, M; Soback, S, 1999) |
| "Treatment with norfloxacin induced the development of quinolone-resistant E." | 1.30 | Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences. ( Aparicio, JR; Arroyo, A; Carnicer, F; de Vera, F; Girona, E; Gutiérrez, A; Palazón, JM; Pascual, S; Pérez-Mateo, M; Plazas, J; Such, J, 1999) |
| " Bioavailability studies in mice showed that 4 liberated a higher concentration of NFLX in plasma than NFLX itself when administered orally." | 1.28 | Studies on prodrugs. 11. Synthesis and antimicrobial activity of N-[(4-methyl-5-methylene-2-oxo-1,3-dioxolan-4-yl)oxy]norfloxacin . ( Kawahata, Y; Kondo, H; Sakamoto, F; Tsukamoto, G; Uno, T, 1989) |
| "Fleroxacin was more potent than norfloxacin." | 1.27 | Comparative activities of norfloxacin and fleroxacin in experimental infections due to Salmonella typhimurium and Escherichia coli. ( Fabrig, J; Hof, H, 1988) |
| "Norfloxacin was ineffective at 200 mg/kg per day against E." | 1.27 | In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. ( Bower, RR; Chu, DT; Fernandes, PB; Jarvis, KP; Ramer, NR; Shipkowitz, N, 1986) |
| "Norfloxacin was the most active antimicrobial agent tested against all isolates studied; it was the only agent active against P." | 1.27 | Comparative in vitro activities of norfloxacin (MK-0366) and six commonly used antimicrobial agents against 199 urinary isolates showing various degrees of antibiotic resistance. ( Appleman, MD; Corigliano, BE; Heseltine, PN; Leedom, JM, 1984) |
| "Norfloxacin was substantially more effective than trimethoprim-sulphamethoxazole in reducing the number of colony forming units from kidney homogenates when the test animals were diabetic." | 1.27 | Norfloxacin versus trimethoprim-sulphamethoxazole: efficacy in a model of ascending urinary tract infection in normal and streptozotocin-induced diabetic mice. ( Abruzzo, GK; Fromtling, RA; Gadebusch, HH; Gilfillan, EC; Pelak, BA, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (30.59) | 18.7374 |
| 1990's | 30 (35.29) | 18.2507 |
| 2000's | 16 (18.82) | 29.6817 |
| 2010's | 6 (7.06) | 24.3611 |
| 2020's | 7 (8.24) | 2.80 |
| Authors | Studies |
|---|---|
| Kondo, H | 2 |
| Sakamoto, F | 2 |
| Uno, T | 1 |
| Kawahata, Y | 1 |
| Tsukamoto, G | 2 |
| Kawakami, K | 1 |
| Mendonça, N | 1 |
| Leitão, J | 1 |
| Manageiro, V | 1 |
| Ferreira, E | 1 |
| Caniça, M | 1 |
| Yamane, K | 2 |
| Wachino, J | 2 |
| Suzuki, S | 2 |
| Kimura, K | 1 |
| Shibata, N | 1 |
| Kato, H | 1 |
| Shibayama, K | 1 |
| Konda, T | 1 |
| Arakawa, Y | 2 |
| Cattoir, V | 1 |
| Poirel, L | 1 |
| Nordmann, P | 1 |
| Blango, MG | 1 |
| Mulvey, MA | 1 |
| Do, KH | 2 |
| Seo, KW | 1 |
| Byun, JW | 1 |
| Lee, WK | 2 |
| Xavier, MR | 1 |
| Freitas, TS | 1 |
| Pereira, RLS | 1 |
| Marinho, EM | 1 |
| Bandeira, PN | 1 |
| de Sousa, AP | 1 |
| Oliveira, LS | 1 |
| Bezerra, LL | 1 |
| Neto, JBA | 1 |
| Silva, MMC | 1 |
| Cruz, BG | 1 |
| Rocha, JE | 1 |
| Barbosa, CRS | 1 |
| da Silva, AW | 1 |
| de Menezes, JESA | 1 |
| Coutinho, HDM | 1 |
| Marinho, MM | 1 |
| Marinho, ES | 1 |
| Dos Santos, HS | 1 |
| Teixeira, AMR | 1 |
| Arafa, SH | 1 |
| Alshehri, WA | 1 |
| Organji, SR | 1 |
| Elbanna, K | 1 |
| Obaid, NA | 1 |
| Aldosari, MS | 1 |
| Asiri, FH | 1 |
| Ahmad, I | 1 |
| Abulreesh, HH | 1 |
| Seo, K | 1 |
| Araújo, MRB | 1 |
| Sant'Anna, LO | 1 |
| Santos, NNCD | 1 |
| Seabra, LF | 1 |
| Santos, LSD | 1 |
| Al-Ajmi, D | 1 |
| Rahman, S | 1 |
| Banu, S | 1 |
| Gerstel, A | 1 |
| Zamarreño Beas, J | 1 |
| Duverger, Y | 1 |
| Bouveret, E | 1 |
| Barras, F | 1 |
| Py, B | 1 |
| González-Soltero, R | 1 |
| García-Cañas, A | 1 |
| Mohedano, RB | 1 |
| Mendoza-Chamizo, B | 1 |
| Botello, E | 1 |
| Themphachanal, M | 1 |
| Kongpheng, S | 1 |
| Rattanachuay, P | 1 |
| Khianngam, S | 1 |
| Singkhamanan, K | 1 |
| Sukhumungoon, P | 1 |
| Machuca, J | 1 |
| Ortiz, M | 1 |
| Recacha, E | 1 |
| Díaz-De-Alba, P | 1 |
| Docobo-Perez, F | 1 |
| Rodríguez-Martínez, JM | 1 |
| Pascual, Á | 1 |
| Kishii, R | 1 |
| Takei, M | 1 |
| Hedelin, H | 1 |
| Claesson, BE | 1 |
| Wilpart, A | 1 |
| Fallah, F | 1 |
| Karimi, A | 1 |
| Goudarzi, M | 1 |
| Shiva, F | 1 |
| Navidinia, M | 1 |
| Jahromi, MH | 1 |
| Sajadi Nia, RS | 1 |
| Sárközy, G | 1 |
| Semjén, G | 1 |
| Laczay, P | 1 |
| Horváth, E | 1 |
| Schmidt, J | 1 |
| Cereto, F | 2 |
| Molina, I | 1 |
| González, A | 2 |
| Del Valle, O | 1 |
| Esteban, R | 2 |
| Guardia, J | 2 |
| Genescà, J | 2 |
| Lecleire, S | 1 |
| Di Fiore, F | 1 |
| Hervé, S | 1 |
| Goria, O | 1 |
| Savoye, G | 1 |
| Colin, R | 1 |
| Lerebours, E | 1 |
| Chakraborty, S | 1 |
| Khan, A | 1 |
| Kahali, S | 1 |
| Faruque, SM | 1 |
| Yamasaki, S | 1 |
| Ramamurthy, T | 1 |
| Turnidge, J | 1 |
| McCarthy, LR | 1 |
| Master, RN | 1 |
| Kepner, DE | 1 |
| Meiland, R | 1 |
| Geerlings, SE | 1 |
| De Neeling, AJ | 2 |
| Hoepelman, AI | 1 |
| Komp Lindgren, P | 1 |
| Marcusson, LL | 1 |
| Sandvang, D | 1 |
| Frimodt-Møller, N | 1 |
| Hughes, D | 1 |
| Rylander, M | 2 |
| Norrby, SR | 3 |
| Corigliano, BE | 1 |
| Appleman, MD | 1 |
| Heseltine, PN | 1 |
| Leedom, JM | 1 |
| Carratalá, J | 1 |
| Fernández-Sevilla, A | 1 |
| Tubau, F | 1 |
| Callis, M | 1 |
| Gudiol, F | 1 |
| Runyon, BA | 1 |
| Borzio, M | 1 |
| Young, S | 1 |
| Squier, SU | 1 |
| Guarner, C | 2 |
| Runyon, MA | 1 |
| Castellote, J | 1 |
| Xiol, J | 1 |
| Rota Roca, R | 1 |
| Fernandez Esparrach, G | 1 |
| Pérez-Trallero, E | 1 |
| Urbieta, M | 1 |
| Jimenez, D | 1 |
| García-Arenzana, JM | 1 |
| Cilla, G | 1 |
| Trienekens, TA | 1 |
| London, NH | 1 |
| Houben, AW | 1 |
| De Jong, RA | 1 |
| Stobberingh, EE | 1 |
| Pascual, J | 1 |
| Orofino, L | 1 |
| Hernández, E | 1 |
| Liaño, F | 1 |
| García-González, R | 1 |
| Ortunño, J | 1 |
| Aguilar, L | 2 |
| Balcabao, IP | 1 |
| Salvá, P | 1 |
| Martín, M | 1 |
| Costa, J | 1 |
| Prieto, J | 1 |
| Dal-ré, R | 2 |
| Del Río, G | 1 |
| Dalet, F | 1 |
| Caffaratti, J | 1 |
| Oyofo, BA | 1 |
| Peruski, LF | 1 |
| Ismail, TF | 1 |
| el-Etr, SH | 1 |
| Churilla, AM | 1 |
| Wasfy, MO | 1 |
| Petruccelli, BP | 1 |
| Gabriel, ME | 1 |
| Albitar, S | 1 |
| Genin, R | 1 |
| Fen-Chong, M | 1 |
| Schohn, D | 1 |
| Riviere, JP | 1 |
| Serveaux, MO | 1 |
| Chuet, C | 1 |
| Ozeki, S | 1 |
| Deguchi, T | 1 |
| Yasuda, M | 1 |
| Nakano, M | 1 |
| Kawamura, T | 1 |
| Nishino, Y | 1 |
| Kawada, Y | 1 |
| Chisaki, T | 1 |
| Hinotani, K | 1 |
| Shimizu, T | 1 |
| Miyazaki, K | 1 |
| Sakata, H | 1 |
| Maruyama, S | 1 |
| Sumano, LH | 1 |
| Ocampo, CL | 1 |
| Brumbaugh, GW | 1 |
| Lizarraga, RE | 1 |
| Martino, R | 1 |
| Subira, M | 1 |
| Altés, A | 1 |
| López, R | 1 |
| Sureda, A | 1 |
| Domingo-Albós, A | 1 |
| Pericas, R | 1 |
| Brunet, S | 1 |
| Ortiz, J | 1 |
| Vila, MC | 1 |
| Soriano, G | 1 |
| Miñana, J | 1 |
| Gana, J | 1 |
| Mirelis, B | 1 |
| Novella, MT | 1 |
| Coll, S | 1 |
| Sábat, M | 1 |
| Andreu, M | 1 |
| Prats, G | 1 |
| Solá, R | 1 |
| Gips, M | 1 |
| Soback, S | 1 |
| Aparicio, JR | 2 |
| Such, J | 2 |
| Pascual, S | 1 |
| Arroyo, A | 2 |
| Plazas, J | 1 |
| Girona, E | 1 |
| Gutiérrez, A | 2 |
| de Vera, F | 1 |
| Palazón, JM | 1 |
| Carnicer, F | 1 |
| Pérez-Mateo, M | 2 |
| Kurioka, T | 1 |
| Yunou, Y | 1 |
| Harada, H | 1 |
| Kita, E | 1 |
| Yoshimura, K | 1 |
| Fujii, J | 1 |
| Taniguchi, H | 1 |
| Yoshida, S | 1 |
| Plaza, J | 1 |
| Sawamura, S | 1 |
| Tanaka, K | 1 |
| Koga, Y | 1 |
| Tavío, MM | 1 |
| Vila, J | 1 |
| Ruiz, J | 2 |
| Martín-Sánchez, AM | 1 |
| Jiménez de Anta, MT | 1 |
| Goettsch, W | 1 |
| van Pelt, W | 1 |
| Nagelkerke, N | 1 |
| Hendrix, MG | 1 |
| Buiting, AG | 1 |
| Petit, PL | 1 |
| Sabbe, LJ | 1 |
| van Griethuysen, AJ | 1 |
| Oluoch, AO | 1 |
| Kim, CH | 1 |
| Weisiger, RM | 1 |
| Koo, HY | 1 |
| Siegel, AM | 1 |
| Campbell, KL | 1 |
| Burke, TJ | 1 |
| McKiernan, BC | 1 |
| Kakoma, I | 1 |
| Cronberg, S | 1 |
| Banke, S | 1 |
| Bergman, B | 1 |
| Boman, H | 1 |
| Eilard, T | 1 |
| Elbel, E | 1 |
| Hugo-Persson, M | 1 |
| Johansson, E | 1 |
| Kuylenstierna, N | 1 |
| Lanbeck, P | 1 |
| Lindblom, A | 1 |
| Paulsen, O | 1 |
| Schönbeck, C | 1 |
| Walder, M | 1 |
| Wieslander, P | 1 |
| Smithson, A | 1 |
| Moreno, G | 1 |
| del Valle Ortiz, O | 1 |
| Schaeffer, AJ | 2 |
| Anderson, RU | 1 |
| Saginur, R | 1 |
| Nicolle, LE | 1 |
| Thornton, SA | 1 |
| Wignall, SF | 1 |
| Kilpatrick, ME | 1 |
| Bourgeois, AL | 1 |
| Gardiner, C | 1 |
| Batchelor, RA | 1 |
| Burr, DH | 1 |
| Oprandy, JJ | 1 |
| Garst, P | 1 |
| Hyams, KC | 1 |
| Li, ZR | 1 |
| Guo, HY | 1 |
| Zhang, ZP | 1 |
| Darras, FS | 1 |
| Seidmon, EJ | 1 |
| Krisch, EB | 1 |
| Truant, AL | 1 |
| Amy, BG | 1 |
| Childs, SJ | 1 |
| Hurst, AT | 1 |
| McCabe, RE | 1 |
| Moran, DB | 1 |
| Ziegler, CB | 1 |
| Dunne, TS | 1 |
| Kuck, NA | 1 |
| Lin, YI | 1 |
| Obana, Y | 1 |
| Nishino, T | 1 |
| Wolfson, JS | 1 |
| Hooper, DC | 1 |
| Shih, DJ | 1 |
| McHugh, GL | 1 |
| Swartz, MN | 1 |
| Wiström, J | 1 |
| Jertborn, M | 1 |
| Hedström, SA | 1 |
| Alestig, K | 1 |
| Englund, G | 1 |
| Jellheden, B | 1 |
| Aoyama, H | 1 |
| Sato, K | 1 |
| Kato, T | 1 |
| Hirai, K | 1 |
| Mitsuhashi, S | 1 |
| Guy, H | 1 |
| Caillot, D | 1 |
| Solary, E | 1 |
| Bielefeld, P | 1 |
| Portier, H | 1 |
| Kazmierczak, A | 1 |
| Yamaguchi, K | 1 |
| Kawaguchi, K | 1 |
| Falck, L | 1 |
| Bucht, H | 1 |
| Stegmayr, B | 1 |
| Svärd, R | 2 |
| Michéa-Hamzehpour, M | 1 |
| Pechère, JC | 1 |
| Marchou, B | 1 |
| Auckenthaler, R | 1 |
| Aoki, T | 1 |
| Shimizu, N | 1 |
| Tomizawa, I | 1 |
| Takizawa, Y | 1 |
| Matsubara, Y | 1 |
| Seo, T | 1 |
| Sagara, H | 1 |
| Tagawa, K | 1 |
| Masuda, G | 1 |
| Negishi, M | 1 |
| Gargallo, D | 1 |
| Moros, M | 1 |
| Coll, R | 1 |
| Esteve, M | 1 |
| Parés, J | 1 |
| Xicota, MA | 1 |
| Guinea, J | 1 |
| Hof, H | 1 |
| Fabrig, J | 1 |
| Stein, GE | 1 |
| Mummaw, N | 1 |
| Goldstein, EJ | 1 |
| Boyko, EJ | 1 |
| Reller, LB | 1 |
| Kurtz, TO | 1 |
| Miller, K | 1 |
| Cox, CE | 1 |
| Dubini, F | 1 |
| Riviera, L | 1 |
| Visconti, A | 1 |
| Sheikh, MA | 1 |
| Naqvi, SA | 1 |
| Fernandes, PB | 1 |
| Chu, DT | 1 |
| Bower, RR | 1 |
| Jarvis, KP | 1 |
| Ramer, NR | 1 |
| Shipkowitz, N | 1 |
| Shibl, AM | 1 |
| Hackbarth, CJ | 1 |
| Sande, MA | 1 |
| Boelaert, J | 1 |
| de Jaegere, PP | 1 |
| Daneels, R | 1 |
| Schurgers, M | 1 |
| Gordts, B | 1 |
| van Landuyt, HW | 1 |
| Joost, J | 1 |
| Shah, PM | 1 |
| Modak, S | 1 |
| Fox, CL | 1 |
| Babu, SC | 1 |
| Sampath, L | 1 |
| Clauss, RH | 1 |
| Stahl, WM | 1 |
| Fromtling, RA | 1 |
| Abruzzo, GK | 1 |
| Gilfillan, EC | 1 |
| Pelak, BA | 1 |
| Gadebusch, HH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rifaximin Versus Norfloxacin in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis[NCT04159870] | Phase 3 | 322 participants (Anticipated) | Interventional | 2019-11-05 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 trials available for norfloxacin and E coli Infections
| Article | Year |
|---|---|
Pulse and continuous oral norfloxacin treatment of experimentally induced Escherichia coli infection in broiler chicks and turkey poults.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Chickens; Drug Administration Schedule; Escher | 2002 |
Interpretation of the bacteriologic outcome of antibiotic treatment for uncomplicated cystitis: impact of the definition of significant bacteriuria in a comparison of ritipenem acoxil with norfloxacin. Swedish Urinary Tract Infection Study Group.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteriuria; Cystitis; Data Interpretation, Statisti | 1995 |
Treating acute urinary tract infections. An RCT of 3-day versus 7-day norfloxacin.
Topics: Absenteeism; Acute Disease; Adolescent; Adult; Aged; Double-Blind Method; Escherichia coli Infection | 1993 |
Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers.
Topics: Adult; Anti-Infective Agents; Bacteriuria; Cross-Over Studies; Escherichia coli Infections; Fluoroqu | 1996 |
Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations.
Topics: Adult; Anti-Infective Agents; Cystitis; Escherichia coli Infections; Female; Fluoroquinolones; Human | 1996 |
Effectiveness of two fluoroquinolones for the treatment of chronic respiratory disease outbreak in broilers.
Topics: Animals; Anti-Infective Agents; Body Weight; Chickens; Chronic Disease; Disease Outbreaks; Enrofloxa | 1998 |
Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ceftibut | 2001 |
Efficacy and tolerability of norfloxacin vs. ciprofloxacin in complicated urinary tract infection.
Topics: Ciprofloxacin; Drug Administration Schedule; Escherichia coli Infections; Female; Humans; Male; Midd | 1992 |
Single-dose compared with 3-day norfloxacin treatment of uncomplicated urinary tract infection in women. Canadian Infectious Diseases Society Clinical Trials Study Group.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Double-Blind Method; Drug Administration | 1992 |
Norfloxacin compared to trimethoprim/sulfamethoxazole for the treatment of travelers' diarrhea among U.S. military personnel deployed to South America and West Africa.
Topics: Acute Disease; Adolescent; Adult; Africa, Western; Bacterial Infections; Diarrhea; Escherichia coli | 1992 |
Treatment of recurrent urinary tract infection with norfloxacin versus trimethoprim-sulfamethoxazole.
Topics: Adult; Aged; Aged, 80 and over; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Norf | 1990 |
Short-term self-treatment of travellers' diarrhoea with norfloxacin: a placebo-controlled study.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Diarrhea; Double-Blind Method; Escherichia coli; | 1989 |
[Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)].
Topics: Agranulocytosis; Anti-Infective Agents; Cefotaxime; Ceftazidime; Drug Evaluation; Drug Therapy, Comb | 1987 |
A multicenter comparative trial of three-day norfloxacin vs ten-day sulfamethoxazole and trimethoprim for the treatment of uncomplicated urinary tract infections.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Drug Administra | 1987 |
Norfloxacin versus co-trimoxazole for treatment of urinary tract infections in adults: microbiological results of a coordinated multicentre study.
Topics: Anti-Bacterial Agents; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Escherichia | 1987 |
70 other studies available for norfloxacin and E coli Infections
| Article | Year |
|---|---|
Studies on prodrugs. 11. Synthesis and antimicrobial activity of N-[(4-methyl-5-methylene-2-oxo-1,3-dioxolan-4-yl)oxy]norfloxacin .
Topics: Animals; Anti-Infective Agents; Chemical Phenomena; Chemistry; Dioxolanes; Dioxoles; Escherichia col | 1989 |
Studies on prodrugs. 7. Synthesis and antimicrobial activity of 3-formylquinolone derivatives.
Topics: Animals; Anti-Bacterial Agents; Biological Availability; Ciprofloxacin; Escherichia coli Infections; | 1988 |
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Community-Acquired Infections; Cross Infection; Drug R | 2007 |
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chitosan; Con | 2007 |
Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.
Topics: Anti-Bacterial Agents; Conjugation, Genetic; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulse | 2008 |
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
Topics: Aged; Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Esch | 2008 |
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cell Membrane Permeability; Cells, Cultured; Drug Resistan | 2010 |
Relationship between virulence factors and antimicrobial resistance genes of pathogenic Escherichia coli from diarrheic weaned piglets.
Topics: Animals; Anti-Bacterial Agents; Cefazolin; Cefoxitin; Diarrhea; Drug Resistance, Bacterial; Enteroto | 2022 |
Anti-inflammatory effect, antibiotic potentiating activity against multidrug-resistant strains of Escherichia coli and Staphylococcus aureus, and evaluation of antibiotic resistance mechanisms by the ibuprofen derivative methyl 2-(-4-isobutylphenyl)propan
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Escherichi | 2022 |
Antimicrobial Resistance, Virulence Factor-Encoding Genes, and Biofilm-Forming Ability of Community-Associated Uropathogenic
Topics: Agar; Ampicillin; Animals; Anti-Bacterial Agents; Biofilms; Drug Resistance, Bacterial; Ertapenem; E | 2022 |
Molecular characteristics of fluoroquinolone-resistant Escherichia coli isolated from suckling piglets with colibacillosis.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; beta-Lactamases; Ciprofloxacin; DNA Gyrase; Enroflo | 2022 |
Monitoring fluoroquinolone resistance among ESBL-positive and ESBL-negative Escherichia coli strains isolated from urinary tract infections: An alert for empirical treatment.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ciprofloxacin; Community-Acquired Infections; Escherichia co | 2023 |
Occurrence, virulence genes, and antimicrobial profiles of Escherichia coli O157 isolated from ruminants slaughtered in Al Ain, United Arab Emirates.
Topics: Animals; Anti-Bacterial Agents; Camelus; Cattle; Cefotaxime; Chloramphenicol; Ciprofloxacin; Escheri | 2020 |
Oxidative stress antagonizes fluoroquinolone drug sensitivity via the SoxR-SUF Fe-S cluster homeostatic axis.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Carrier Proteins; Drug Antagonism; Drug Resistance, Bacte | 2020 |
[Role of double strand DNA break repair for quinolone sensitivity in Escherichia coli: therapeutic implications].
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; DNA Breaks, Double-Stranded; DNA Helicases | 2015 |
MOLECULAR CHARACTERIZATION OF VIRULENCE AND ANTIMICROBIAL SUSCEPTIBILITY PROFILES OF UROPATHOGENIC ESCHERICHIA COLI FROM PATIENTS IN A TERTIARY HOSPITAL, SOUTHERN THAILAND.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Toxins; beta-Lactamases; Ciprofloxacin; Drug Res | 2015 |
Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; Chromosomes, Bacterial; Ciprofloxacin; Disease Models, Animal; Esche | 2016 |
Relationship between the expression of ompF and quinolone resistance in Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; Cell Growth Processes; Ciprofloxacin; Disease Models, Animal; DNA Gy | 2009 |
Febrile reactions after transrectal ultrasound-guided prostatic biopsy: a retrospective study.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy; Drug Resistance, Bacterial; Escherichia coli; | 2011 |
Determination of integron frequency by a polymerase chain reaction-restriction fragment length polymorphism method in multidrug-resistant Escherichia coli, which causes urinary tract infections.
Topics: Adult; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Escherichia coli Infections; Fem | 2012 |
Role of immunosuppression in the development of quinolone-resistant Escherichia coli spontaneous bacterial peritonitis and in the mortality of E. coli spontaneous bacterial peritonitis.
Topics: Anti-Infective Agents; Ascitic Fluid; Drug Resistance, Bacterial; Escherichia coli Infections; Human | 2003 |
[Spontaneous infection of ascitic fluid due to Salmonella typhimurium in a cirrhotic patient undergoing selective intestinal decontamination with norfloxacin].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Ascitic Fluid; Blood; Cefotaxi | 2003 |
Infantile diarrhoea associated with sorbitol-fermenting, non-shiga toxin-producing Escherichia coli O157:H-.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Child, Preschool; Colony Count, Microbial; Combined Modalit | 2003 |
Low levels of fluoroquinolone resistance in Escherichia coli. A five-year trend in Australia measured through the use of TSN Database Australia.
Topics: Australia; Ciprofloxacin; Databases, Factual; Drug Resistance, Bacterial; Escherichia coli; Escheric | 2003 |
Diabetes mellitus in itself is not a risk factor for antibiotic resistance in Escherichia coli isolated from patients with bacteriuria.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Bacteriuria; Ciprofloxacin; Diabetes Co | 2004 |
Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infec | 2005 |
Norfloxacin penetration into subcutaneous tissue cage fluid in rabbits and efficacy in vivo.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Escherichia coli Infections; Klebsiella Infect | 1983 |
Comparative in vitro activities of norfloxacin (MK-0366) and six commonly used antimicrobial agents against 199 urinary isolates showing various degrees of antibiotic resistance.
Topics: Anti-Infective Agents, Urinary; Drug Resistance, Microbial; Escherichia coli Infections; Humans; In | 1984 |
Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin.
Topics: Adult; Aged; Aged, 80 and over; Bacteremia; Drug Resistance, Microbial; Escherichia coli Infections; | 1995 |
Effect of selective bowel decontamination with norfloxacin on spontaneous bacterial peritonitis, translocation, and survival in an animal model of cirrhosis.
Topics: Administration, Oral; Animals; Carbon Tetrachloride Poisoning; Enterobacteriaceae; Enterobacteriacea | 1995 |
Spontaneous bacterial peritonitis and empyema by Escherichia coli resistant to norfloxacine in a patient on selective intestinal decontamination with norfloxacine.
Topics: Drug Resistance, Microbial; Empyema; Escherichia coli Infections; Female; Humans; Incidence; Intesti | 1994 |
Ten-year survey of quinolone resistance in Escherichia coli causing urinary tract infections.
Topics: Anti-Infective Agents; Ciprofloxacin; Data Collection; Drug Resistance, Microbial; Escherichia coli; | 1993 |
Subacute thyroiditis in a renal allograft recipient.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Biopsy, Needle; Cyclosporine; Escherichia coli Infe | 1996 |
Enteropathogens associated with diarrhea among military personnel during Operation Bright Star 96, in Alexandria, Egypt.
Topics: Ampicillin Resistance; Animals; Anti-Infective Agents; Antigens, Bacterial; Bacterial Proteins; Blas | 1997 |
The febrile patient presenting with acute renal failure and enlarged kidneys--another mode of presentation of malakoplakia.
Topics: Acute Kidney Injury; Aged; Anti-Infective Agents; Escherichia coli Infections; Fever; Humans; Kidney | 1997 |
Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections.
Topics: Anti-Infective Agents; Asparagine; Ciprofloxacin; DNA Gyrase; DNA Topoisomerases, Type II; DNA, Bact | 1997 |
[Initial treatment at an outbreak of E. coli O-157:H7 infection: especially with respect to therapy in the emergency].
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Child; Disease Outbreaks; Emerge | 1997 |
[Result of antibiotic therapy for children with Escherichia coli O26:H11 infection].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Child; Disease Outbreaks; Drug Resistance, Microbial; | 1998 |
Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial Infect | 1998 |
Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Ciprofloxacin; Drug Resi | 1999 |
Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Blood Proteins; Cattle; Chromatography, High Press | 1999 |
Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Cross Infection; Drug Resistance, Microbial; Es | 1999 |
Efficacy of antibiotic therapy for infection with Shiga-like toxin-producing Escherichia coli O157:H7 in mice with protein-calorie malnutrition.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Bacterial Toxins; Brain Chemistry; Disease Models, Anima | 1999 |
Chemotherapy for enterohemorrhagic Escherichia coli O157:H infection in a mouse model.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Toxins; Colon | 1999 |
[Development of Escherichia coli strands resistant to quinolones in stools of patients with liver cirrhosis submitted to selective bowel decontamination].
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Escherichia coli; Escherichia coli Infections; | 1999 |
[Therapeutic effects of antibiotics against enterohemorrhagic Escherichia coli (EHEC) O157:H7 (O157) infection: in vivo analysis using germfree mice].
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Toxins; Disease Models, Animal; Esc | 1999 |
Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli isolates.
Topics: Anti-Infective Agents; Bacterial Outer Membrane Proteins; DNA Topoisomerase IV; DNA Topoisomerases, | 1999 |
Increasing resistance to fluoroquinolones in escherichia coli from urinary tract infections in the netherlands.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Drug Resistance, Mic | 2000 |
Nonenteric Escherichia coli isolates from dogs: 674 cases (1990-1998).
Topics: Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Dog Diseases; Dogs; Drug Resistance | 2001 |
Spontaneous bacterial peritonitis caused by quinolone-resistant Escherichia coli: could steroid therapy play a role?
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Drug Resistance, Bacterial; Escherichia coli; E | 2002 |
[Studies on pyridonecarboxylic acids as anti-bacterial agents. IX. Study on prodrugs of some pyridonecarboxylic acids].
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Escherichia coli Infections; Mice; Norfloxacin; Prodr | 1991 |
The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin.
Topics: Carbenicillin; Chronic Disease; Escherichia coli Infections; Follow-Up Studies; Humans; Male; Middle | 1990 |
Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
Topics: Animals; Chemical Phenomena; Chemistry; Ciprofloxacin; Enterobacter; Enterococcus faecalis; Escheric | 1989 |
In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Escherichia coli Infections; Female; Mice; Microbial | 1989 |
Isolation and characterization of an Escherichia coli strain exhibiting partial tolerance to quinolones.
Topics: Anti-Infective Agents; Drug Resistance, Microbial; Escherichia coli; Escherichia coli Infections; Me | 1989 |
Norfloxacin resistance in a clinical isolate of Escherichia coli.
Topics: DNA Topoisomerases, Type II; Drug Resistance, Microbial; Escherichia coli; Escherichia coli Infectio | 1987 |
[Single day treatment in acute cystitis].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Cystitis; | 1988 |
Suppressive therapy with norfloxacin in patients with recurrent and/or complicated urinary tract infection.
Topics: Escherichia coli Infections; Female; Humans; Male; Middle Aged; Norfloxacin; Recurrence; Time Factor | 1988 |
Combination therapy: a way to limit emergence of resistance?
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftriaxone; Drug Resistance, Microbial; Drug Therapy, Com | 1986 |
[Clinical study of AM-715 on acute infectious enteritis. The Japan Research Committee of AM-715, Research Group for Acute Infectious Enteritis].
Topics: Acute Disease; Administration, Oral; Campylobacter Infections; Drug Administration Schedule; Dysente | 1986 |
Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.
Topics: Animals; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacteria; Chemical Phenomena; Chemis | 1988 |
Comparative activities of norfloxacin and fleroxacin in experimental infections due to Salmonella typhimurium and Escherichia coli.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Escherichia coli Infections; Female; Fleroxacin; Mice | 1988 |
[Experimental cystitis in the rat and the therapeutic effect of a single dose of fosfomycin trometamol].
Topics: Animals; Cystitis; Drug Combinations; Drug Evaluation, Preclinical; Escherichia coli Infections; Fos | 1987 |
A study of the use of norfloxacin in prostatitis.
Topics: Adult; Escherichia coli Infections; Humans; Male; Norfloxacin; Prostatitis; Staphylococcal Infection | 1987 |
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enterobacteriaceae In | 1986 |
Evaluation of pefloxacin in experimental Escherichia coli meningitis.
Topics: Animals; Anti-Infective Agents; Cefotaxime; Chloramphenicol; Escherichia coli Infections; Humans; Me | 1986 |
Case report of renal failure during norfloxacin therapy.
Topics: Acute Kidney Injury; Aged; Escherichia coli Infections; Female; Humans; Norfloxacin; Urinary Tract I | 1986 |
[Norfloxacin in the treatment of urinary tract infections].
Topics: Adolescent; Adult; Aged; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Norfloxacin | 1986 |
PTFE graft treated with silver norfloxacin (AgNF): drug retention and resistance to bacterial challenge.
Topics: Animals; Anti-Infective Agents; Blood Vessel Prosthesis; Dogs; Escherichia coli Infections; Fluoroqu | 1987 |
Norfloxacin versus trimethoprim-sulphamethoxazole: efficacy in a model of ascending urinary tract infection in normal and streptozotocin-induced diabetic mice.
Topics: Animals; Anti-Infective Agents; Diabetes Mellitus, Experimental; Disease Models, Animal; Drug Combin | 1985 |